Skip to content

Revolution Medicines Inc Sustainability Reports

Revolution Medicines Inc. is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The company focuses on expanding its portfolio of RAS(ON) inhibitors and RAS companion inhibitors to outsmart difficult cancer pathways.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

LEI: 549300JU3X0LBCQ65892

FIGI: BBG00829F4Q7

3 reports from 2020 to 2023